Solara Active Pharma Sciences Limited (BOM:541540)

India flag India · Delayed Price · Currency is INR
521.15
-1.70 (-0.33%)
At close: Apr 21, 2025
-4.76%
Market Cap 24.92B
Revenue (ttm) 13.10B
Net Income (ttm) -2.53B
Shares Out n/a
EPS (ttm) -97.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 805
Average Volume 8,915
Open 517.00
Previous Close 522.85
Day's Range 512.05 - 526.65
52-Week Range 366.95 - 885.95
Beta n/a
RSI 55.91
Earnings Date Apr 29, 2025

About BOM:541540

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antif... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2017
Employees 2,156
Stock Exchange Bombay Stock Exchange
Ticker Symbol 541540
Full Company Profile

Financial Performance

In 2023, BOM:541540's revenue was 12.89 billion, a decrease of -10.73% compared to the previous year's 14.44 billion. Losses were -5.67 billion, 2458.1% more than in 2022.

Financial Statements

News

Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns

Shares of Solara Active Pharma Sciences Ltd declined 5% in early trade on February 24, following the announcement of Managing Director (MD) and CEO Poorvank Purohit’s resignation. The stock dropped to...

2 months ago - Business Upturn

Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business

Solara Active Pharma Sciences has announced the demerger of its CRAMS (Contract Research and Manufacturing Services) and Polymers business from the Generic API business (Catalog API). The move is expe...

3 months ago - Business Upturn

Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore

Solara Active Pharma Sciences Limited announced its financial results for the quarter ended December 31, 2024, showing a consistent performance across key financial metrics. Key Financial Highlights: ...

3 months ago - Business Upturn